# A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401

> **NCT01627002** · PHASE1 · TERMINATED · sponsor: **ProtAffin Biotechnologie AG** · enrollment: 49 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** PA401
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01627002
- **Lead sponsor:** ProtAffin Biotechnologie AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2013-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627002, "A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01627002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*